TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07322887: A Phase 2, Randomized, Double-blind, Placebo-Controlled, Single-Center Study to Assess the Effects of SUL-238 on High Energy Phosphates With Magnetic Resonance Spectroscopy (³¹P-MRS) in Patients With Early, Untreated Par

Sponsor: GEN İlaç ve Sağlık Ürünleri A.Ş. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 45 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT07322887 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07322887 Rescue Dossier →